Haemonetics Co. (NYSE:HAE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Haemonetics Co. (NYSE:HAE) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $108.78.

Several equities analysts have commented on HAE shares. BTIG Research started coverage on Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Barrington Research reiterated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a report on Wednesday, December 4th. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a report on Friday, November 8th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. Finally, Bank of America started coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective for the company.

Haemonetics Stock Performance

Shares of HAE opened at $77.57 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics has a 12 month low of $70.25 and a 12 month high of $97.97. The company’s fifty day moving average is $81.59 and its 200-day moving average is $81.02. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of 32.19, a price-to-earnings-growth ratio of 1.29 and a beta of 0.38.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company earned $0.99 earnings per share. Equities analysts expect that Haemonetics will post 4.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors have recently bought and sold shares of HAE. Quarry LP bought a new position in shares of Haemonetics during the 2nd quarter worth about $39,000. Daiwa Securities Group Inc. bought a new position in Haemonetics during the second quarter worth about $82,000. Canada Pension Plan Investment Board acquired a new stake in Haemonetics during the second quarter valued at approximately $83,000. Nisa Investment Advisors LLC grew its stake in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Haemonetics in the 2nd quarter worth approximately $140,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.